Literature DB >> 10473081

Overexpression of cyclooxygenase-2 in carcinoma of the pancreas.

J Okami1, H Yamamoto, Y Fujiwara, M Tsujie, M Kondo, S Noura, S Oshima, H Nagano, K Dono, K Umeshita, O Ishikawa, M Sakon, N Matsuura, S Nakamori, M Monden.   

Abstract

The level of cyclooxygenase (COX)-2 has been investigated recently in various human carcinomas. In the present study, we examined the distribution and extent of COX-2 protein in human pancreatic tumors using immunohistochemistry. A strong expression of COX-2 protein was present in 23 of 52 (44%) pancreatic carcinomas, a moderate expression was present in 24 of 52 (46%) pancreatic carcinomas, and a weak expression was present in 5 of 52 (10%) pancreatic carcinomas. In contrast, benign tumors showed weak expression or no expression of COX-2, and only islet cells displayed COX-2 expression in normal pancreatic tissues. Overexpression of COX-2 in carcinoma tissues was also confirmed by Western blot analysis. Furthermore, consistent with the results at protein levels, reverse transcription-PCR analyses indicated that COX-2 mRNA was overexpressed in 7 of 13 (54%) carcinomas, but in none of 3 benign tumors. Our findings suggest that COX-2 inhibitors might be potentially effective against pancreatic carcinomas and that COX-2 may be involved in certain biological processes in pancreatic islets.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473081

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  61 in total

Review 1.  Chemoprevention for pancreatic cancer.

Authors:  Robert A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  Roles of ROS, Nrf2, and autophagy in cadmium-carcinogenesis and its prevention by sulforaphane.

Authors:  Yuting Wang; Ardhendu Kumar Mandal; Young-Ok Son; Poyil Pratheeshkumar; James T F Wise; Lei Wang; Zhuo Zhang; Xianglin Shi; Zhimin Chen
Journal:  Toxicol Appl Pharmacol       Date:  2018-06-06       Impact factor: 4.219

Review 3.  Pancreatic cancer: pathogenesis, prevention and treatment.

Authors:  Fazlul H Sarkar; Sanjeev Banerjee; Yiwei Li
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-11       Impact factor: 4.219

4.  Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.

Authors:  Antonio Lozano-Leon; Begona Vieites Perez-Quintela; Julio Iglesias-García; Jose Lariño-Noia; Evaristo Varo; Jeronimo Forteza; J Enrique Domínguez-Muñoz
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

5.  5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue.

Authors:  René Hennig; Xian-Zhong Ding; Wei-Gang Tong; Matthias B Schneider; Jens Standop; Helmut Friess; Markus W Büchler; Parviz M Pour; Thomas E Adrian
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.

Authors:  Jingjing Gong; Jianping Xie; Roble Bedolla; Paul Rivas; Divya Chakravarthy; James W Freeman; Robert Reddick; Scott Kopetz; Amanda Peterson; Huamin Wang; Susan M Fischer; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

7.  Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor.

Authors:  Chantale Charo; Vijaykumar Holla; Thiruvengadam Arumugam; Rosa Hwang; Peiying Yang; Raymond N Dubois; David G Menter; Craig D Logsdon; Vijaya Ramachandran
Journal:  Pancreas       Date:  2013-04       Impact factor: 3.327

Review 8.  The Role of Nutraceuticals in Pancreatic Cancer Prevention and Therapy: Targeting Cellular Signaling, MicroRNAs, and Epigenome.

Authors:  Yiwei Li; Vay Liang W Go; Fazlul H Sarkar
Journal:  Pancreas       Date:  2015-01       Impact factor: 3.327

Review 9.  The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells.

Authors:  Mathias Gehrmann; Jürgen Radons; Michael Molls; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2008-02-05       Impact factor: 3.667

10.  Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor.

Authors:  Jiro Okami; Shoji Nakamori; Nobuaki Hiraoka; Masanori Tsujie; Nobuyasu Hayashi; Hirofumi Yamamoto; Yoshiyuki Fujiwara; Hiroaki Nagano; Keizo Dono; Koji Umeshita; Masato Sakon; Morito Monden
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.